Test Price
2,800 AED✅ Home Collection Available
POU4F3 Gene (Autosomal Dominant Deafness Type 52) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% analytical sensitivity via ISO‑certified next‑generation sequencing with Sanger confirmation, ensuring precise detection of pathogenic POU4F3 variants.
- Premium Home Collection: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM across all UAE emirates.
- Post‑Test Clinical Guidance: Complimentary tele‑consultation with a DHA‑licensed consultant medical geneticist to interpret results and guide family risk assessment.
- Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
This single‑gene analysis detects autosomal dominant non‑syndromic hearing loss (DFNA52) with clinical‑grade reliability. Results are delivered within three to four weeks accompanied by expert genetic counselling to support informed medical decisions.
Test Overview & Methodology
The POU4F3 Genetic Test identifies pathogenic variants in the POU4F3 gene, confirming hereditary autosomal dominant non‑syndromic hearing loss (DFNA52). This targeted analysis uses next‑generation sequencing with Sanger validation for clinically actionable results. The POU4F3 gene encodes a POU‑domain transcription factor essential for the development and survival of inner ear hair cells. Pathogenic variants cause progressive sensorineural hearing loss typically beginning in early to mid‑adulthood, with high penetrance across generations.
| Feature | Our Test (DHA‑Approved) | Closest Alternative (Commercial Panels) |
|---|---|---|
| Precision | Single‑gene deep coverage (99.9% analytical sensitivity) | Broad panel with possible incidental findings |
| Methodology | NGS + Sanger confirmation, ISO‑certified lab | NGS only, variable validation |
| Turnaround Speed | 3–4 weeks with result‑specific genetic counselling | 4–6 weeks, raw data only |
Physician Insight & Safety Protocols
A positive POU4F3 result provides your family with a clear genetic explanation for progressive hearing loss, enabling precise risk counselling and early intervention strategies. Every result must be interpreted alongside a comprehensive audiogram and three‑generation pedigree. I encourage patients to bring a support person to the counselling session to ensure all questions are addressed thoroughly.
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Continue all current prescriptions as directed by your treating physician. This genetic test does not alter the safety or efficacy of any ongoing therapy. Consult your doctor before making any medication changes.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Children under 18 years without legal guardian consent (minors’ genetic testing regulated by UAE Federal Law).
- Active systemic infection or severe coagulopathy that contraindicates safe venipuncture.
- Unwillingness to participate in mandatory pre‑test genetic counselling required for clinical validity.
Emergency Red Flags
Seek immediate medical attention if you experience: sudden vision changes, vertigo with vomiting, or new‑onset tinnitus after any procedure. These symptoms may indicate a separate acute condition requiring urgent evaluation.
Patient FAQ & Clinical Guidance
1. What does a positive POU4F3 mutation result mean for my hearing?
Snippet: A positive result confirms a genetic cause of autosomal dominant hearing loss, enabling precise risk assessment for family members.
The POU4F3 gene is essential for inner ear hair cell function; a pathogenic variant leads to progressive sensorineural hearing loss that usually starts in adulthood. Genetic counselling explains the inheritance pattern and implications for children and siblings. Surveillance with serial audiograms and hearing preservation strategies can be tailored to the expected natural history of DFNA52.
2. How is the sample collected and how long do results take?
Snippet: Home collection by DHA‑licensed phlebotomists is available daily 8 AM to 11 PM, with results ready in 3–4 weeks.
A small volume of whole blood, extracted DNA, or a single drop on an FTA card is all that is required. The sample travels in a temperature‑controlled cold chain to our ISO‑accredited laboratory, ensuring DNA integrity throughout transport. Sequencing and bioinformatic analysis are performed in batches to guarantee quality metrics before clinical reporting.
3. Is the POU4F3 genetic test covered by UAE medical insurance?
Snippet: Many UAE insurers cover diagnostic genetic testing when supported by an ENT or clinical geneticist referral; our team verifies coverage instantly via WhatsApp.
We handle direct billing verification with major providers. Send your insurance card photo to +971 54 548 8731 and receive a pre‑authorization update within one working hour. Prior approval depends on your policy terms and the presence of a clinical indication documented by your referring physician.
UAE Regulatory & Data Privacy Adherence
All genetic data are processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent requirements follow Federal Decree‑Law No. 4 of 2016 on Medical Liability. Laboratory operations hold ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139), ensuring quality, traceability, and international compliance.
Patient genomic data are anonymised, encrypted, and stored on UAE‑based servers. Access is restricted to authorised clinical personnel only. Results are released exclusively to the ordering physician or the patient following verified identity confirmation.
Clinical & Logistical Metadata
| Test Name | POU4F3 Gene (Autosomal Dominant Deafness Type 52) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood, Extracted DNA, or FTA Card |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger Confirmation |
| ICD‑10‑CM Code | H90.3 |
| LOINC Code | 94121-4 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians